{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:01:28Z","timestamp":1794744088853,"version":"4.9.1"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.285933","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T03:17:15Z","timestamp":1730949435000},"page":"764-767","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma"],"prefix":"10.3324","volume":"110","author":[{"given":"Jessie","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Khong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Gorniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zac","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridurga","family":"Mithraprabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suehli","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Motorna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"73464","doi-asserted-by":"crossref","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020; 4(23):5988-5999.","DOI":"10.1182\/bloodadvances.2020002827"},{"key":"73465","doi-asserted-by":"crossref","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346.","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"73466","doi-asserted-by":"crossref","unstructured":"Mithraprabhu S, Khong T, Ramachandran M. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. Leukemia. 2017; 31(8):1695-1705.","DOI":"10.1038\/leu.2016.366"},{"key":"73467","doi-asserted-by":"crossref","unstructured":"Barnidge DR, Dasari S, Botz CM. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J Proteome Res. 2014; 13(3):1419-1427.","DOI":"10.1021\/pr400985k"},{"key":"73468","doi-asserted-by":"crossref","unstructured":"Murray DL, Puig N, Kristinsson S. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021; 11(2):24.","DOI":"10.1038\/s41408-021-00408-4"},{"key":"73469","doi-asserted-by":"crossref","unstructured":"Bergen HR, Dasari S, Dispenzieri A. Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration. Clin Chem. 2016; 62(1):243-251.","DOI":"10.1373\/clinchem.2015.242651"},{"key":"73470","doi-asserted-by":"crossref","unstructured":"Lim S, Reynolds J, Quach H. Preliminary analysis of the MM21 trial: response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone (DRd) for newly diagnosed transplant eligible multiple myeloma patients failing front-line bortezomib-based induction therapy. Blood. 2021; 138(Suppl 1):1665.","DOI":"10.1182\/blood-2021-152102"},{"key":"73471","doi-asserted-by":"crossref","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017; 31(10):2094-2103.","DOI":"10.1038\/leu.2017.29"},{"key":"73472","doi-asserted-by":"crossref","unstructured":"Arroz M, Came N, Lin P. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016; 90(1):31-39.","DOI":"10.1002\/cyto.b.21228"},{"key":"73473","doi-asserted-by":"crossref","unstructured":"Liyasova M, McDonald Z, Taylor P. A personalized mass spectrometry-based assay to monitor M-protein in patients with multiple myeloma (EasyM). Clin Cancer Res. 2021; 27(18):5028-5037.","DOI":"10.1158\/1078-0432.CCR-21-0649"},{"key":"73474","doi-asserted-by":"crossref","unstructured":"Noori S, Wijnands C, Langerhorst P. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J. 2023; 13(1):30.","DOI":"10.1038\/s41408-023-00803-z"},{"key":"73475","doi-asserted-by":"crossref","unstructured":"Slade MJ, Khalid A, Fiala MA. Clonotypic mass spectrometry with EasyM assay for detection of measurable residual disease in multiple myeloma. Blood. 2022; 140(Suppl 1):4376-4377.","DOI":"10.1182\/blood-2022-155582"},{"key":"73476","doi-asserted-by":"crossref","unstructured":"Fan H, Wang B, Qiu L, Ma B, An G. Monitoring minimal residual disease in patients with multiple myeloma by tracking serum M-protein using mass spectrometry. Blood. 2023; 142(Suppl 1):1920.","DOI":"10.1182\/blood-2023-181761"},{"key":"73477","doi-asserted-by":"crossref","unstructured":"Slade M, Khaled A, Fiala M. Measurable residual disease status by clonotypic mass spectrometry with EasyM assay predicts outcomes following autologous hematopoietic cell transplant in multiple myeloma. Blood. 2023; 142(Suppl 1):3354.","DOI":"10.1182\/blood-2023-172440"},{"key":"73478","doi-asserted-by":"crossref","unstructured":"Fonseca R, Arribas M, Wiedmeier-Nutor JE. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023; 13(1):32.","DOI":"10.1038\/s41408-023-00794-x"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285933\/77746","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285933\/78132","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285933\/77746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:06:26Z","timestamp":1794071186000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285933","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,7]]}}}